Margot Zöller
Heidelberg University
252 Papers
2.9K Citations
Margot Zöller is an academic researcher from Heidelberg University. The author has contributed to research in topics: CD44 & Antigen. The author has an hindex of 56, co-authored 250 publications. Previous affiliations of Margot Zöller include Merck & Co. & German Cancer Research Center.
Chat about Author
Papers
CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells
TL;DR: Fundamental progress in support of this “old” hypothesis, which may soon pave the way for most promising new therapeutics, is presented for both hematopoietic stem cell and leukemia-initiating cell.
Serological analysis of human renal cell carcinoma
Gerard Devitt,Christiane Meyer,Nicole Wiedemann,Stefan B. Eichmüller,Annette Kopp-Schneider,Axel Haferkamp,Richard E. Hautmann,Margot Zöller,Margot Zöller +8 more
TL;DR: Serological analysis of cDNA expression libraries (SEREX) has proven to be a useful technique in the quest to elucidate the repertoire of immunogenic gene products in human cancer, and the method was applied to human renal cell carcinoma (RCC) in order to identify associated immunogenic genes products.
•Journal Article
Developmentally Regulated Expression of Metastasis- associated Antigens in the Rat'
TL;DR: Five newly described metastasis-associated antigens share with CD44v the absence of expression on nonmetastasizing tumor lines as well as expression on distinct, nontransformed cells and induction of expression during ontogeny, suggesting that tumor progression may rather be initiated by inappropriate expression or up-regulation of genes, than by de novo appearance of "metastasis genes.
Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization.
TL;DR: It is noted that in irradiated mice reconstituted with a bone marrow cell transplant, anti‐CD44 exerts a stronger effect on haematopoietic reconstitution than on T lymphoma (EL4) growth, and care should be taken not to interfere by a blockade of CD44 with haem atopoiesis, which could be circumvented by selectively targeting leukemic CD44 isoforms.
Tumorigenicity of IL-1α– and IL-1β–Deficient Fibrosarcoma Cells
Irina Nazarenko,Rachid Marhaba,Eli Reich,Elena Voronov,Mario Vitacolonna,Dagmar Hildebrand,Elena Elter,Mohini Rajasagi,Ron N. Apte,Margot Zöller,Margot Zöller +10 more
TL;DR: In vivo growth of IL-1-deficient tumor lines was evaluated in nu/nu mice and was compared with in vitro growth characteristics, finding that stronger tumorigenicity ofIL-1βcomp lines grows more aggressively, efficiently induce angiogenesis, and recruit inflammatory cells.